How does Mazdutide work?
GLP-1 + glucagon dual agonist developed in China. Same dual-receptor strategy as Survodutide. In plain terms, Mazdutide is a weight-loss shot already approved in China. Innovent Biologics' GLP-1 + glucagon dual agonist out of China, with strong Phase 3 data and a 2025 China approval for obesity. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Users wanting a GLP/glucagon agonist with cleaner side effect profile than Survodutide reports
- Followers of Chinese metabolic-drug development
References
- Mazdutide in Chinese adults with obesity (Phase 3) — Ji L et al., Nat Med, 2025
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1) — Ji et al., N Engl J Med, 2025
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity — Ji et al., Nature Communications, 2023
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Mazdutide
Last updated 2026-06-06.